Literature DB >> 18088252

Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.

A Själander1, J-H Jansson, D Bergqvist, H Eriksson, B Carlberg, P Svensson.   

Abstract

OBJECTIVES: Venous thromboembolism (VTE) is a potentially serious complication of hospitalization and immobilization. The use of anticoagulant prophylaxis in acutely ill medical inpatients is still under debate. New data including a recent meta-analysis have recently been published. We aim at studying the efficacy and safety of anticoagulant prophylaxis in acutely ill medical inpatients, and demonstrate differences between meta-analyses due to different data extraction from the heterogeneous studies included.
SUBJECTS: The Cochrane Library, MEDLINE and EMBASE were searched from 1980 to present. Manual searches were performed regarding abstracts from major meetings. Seven blinded randomized controlled clinical trials assessing the prophylactic effect of heparin in acutely ill medical patients were identified and included in the meta-analysis.
RESULTS: Low-molecular weight heparin (LMWH) prophylaxis prevented 48% of symptomatic pulmonary embolism (PE), 48% of symptomatic deep vein thrombosis (DVT) (not significant) and 51% of asymptomatic DVT. A nonsignificant trend towards higher bleeding risk during LMWH prophylaxis was found. Death was not significantly affected. We compared our data with a recent meta-analysis with different study selection and data extraction and found similar results.
CONCLUSIONS: As DVT and PE are manifestations of the same illness, VTE, one can argue that anticoagulant prophylaxis prevents approximately half of the expected events. Most medical inpatients have short hospital stays, and a low risk of VTE. The important task for the clinician is to identify patients with a sufficiently high risk of symptomatic VTE to warrant LMWH prophylaxis. Despite differences in study selection and data extraction, our study shows results similar to a recent meta-analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18088252     DOI: 10.1111/j.1365-2796.2007.01878.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  17 in total

1.  Puerperal ovarian vein thrombosis presenting as rt loin pain and hydronephrosis: report of 2 cases.

Authors:  Manjula Dhinakar; Logesan Dhinakar; Atheel Kamona; Abdulrahman Saifudeen
Journal:  Oman Med J       Date:  2010-10

2.  Impact of risk factors on the timing of first postpartum venous thromboembolism: a population-based cohort study from England.

Authors:  Alyshah Abdul Sultan; Matthew J Grainge; Joe West; Kate M Fleming; Catherine Nelson-Piercy; Laila J Tata
Journal:  Blood       Date:  2014-08-25       Impact factor: 22.113

3.  High inferior vena cava thrombosis in a 16-year-old postpartum patient: a case report.

Authors:  Yong Wei; Ping Ouyang; Wanhua Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

4.  The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis.

Authors:  J L Pleet; B P Vaughn; J A Morris; A C Moss; A S Cheifetz
Journal:  Aliment Pharmacol Ther       Date:  2014-03-10       Impact factor: 8.171

Review 5.  Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Authors:  Ida Ehlers Albertsen; Torben Bjerregaard Larsen; Lars Hvilsted Rasmussen; Thure Filskov Overvad; Gregory Y H Lip
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

6.  DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines.

Authors:  Ignacio Neumann; Ariel Izcovich; Yuqing Zhang; Gabriel Rada; Susan R Kahn; Frederick Spencer; Suely Rezende; Franchesco Dentali; Kenneth Bauer; Gian Paolo Morgano; Juan J Yepes-Nuñez; Robby Nieuwlaat; Wojtek Wiercioch; Liming Lu; Jiaming Wu; Mary Cushman; Holger Schunemann
Journal:  Blood Adv       Date:  2020-04-14

7.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

8.  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Authors:  Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello
Journal:  Blood Adv       Date:  2021-02-23

Review 9.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20

10.  Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.

Authors:  S Phani Veeranki; Zhimin Xiao; Andrée Levorsen; Meenal Sinha; Bimal R Shah
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-14       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.